Is compounded semaglutide the same as Ozempic or Wegovy?▼
Same active ingredient (semaglutide), different formulation, different regulatory status. Ozempic and Wegovy are brand-name drugs made by Novo Nordisk and FDA-approved for specific indications (T2D for Ozempic, chronic weight management plus cardiovascular risk reduction plus pediatric obesity for Wegovy). Compounded semaglutide is prepared by a 503A pharmacy for an individual patient under a valid prescription and is not FDA-approved as a finished product. Both contain the same active ingredient, but the regulatory pathways and quality controls differ. HSA eligibility hinges on the prescription-medicines rule in IRC 213(d), which applies to both as long as the prescription is written by a licensed provider for a qualifying condition.
Why is compounded semaglutide cheaper than brand-name Wegovy?▼
Two reasons. First, the active pharmaceutical ingredient (semaglutide) is purchased in bulk by 503A compounding pharmacies rather than carrying Novo Nordisk's brand markup, R&D recoupment, and direct-to-consumer marketing costs. Second, the compounding step is labor-priced, not platform-priced. Telehealth compounded GLP-1 programs typically run $199 to $349 per month versus brand-name Wegovy at $1,349 per month list price or $499 per month through NovoCare direct-pay. The savings are real, but they come with the regulatory tradeoffs documented on this page.
Can my doctor prescribe compounded semaglutide?▼
Yes if the provider determines compounded semaglutide is clinically appropriate for your situation. Many compounded GLP-1 telehealth services staff licensed prescribers (NP, PA, MD, DO) who issue the prescription after an online intake and provider visit. The provider's clinical judgment plus a documented diagnosis (obesity at BMI 30+, BMI 27+ with comorbidity, or T2D) is what links the prescription to the IRS treatment-of-disease standard. Without that diagnosis and provider relationship, the prescription itself is not legal and HSA eligibility falls apart.
What happens if the FDA changes its position again on compounded semaglutide?▼
Stop ordering. Existing HSA receipts remain documented expenses because the IRS evaluates HSA distributions based on whether the expense was a qualified medical expense at the time it was incurred, not whether the legal landscape later shifts. If 503A compounding of semaglutide becomes restricted, your provider should transition you to brand-name Wegovy or an alternative FDA-approved drug. Your past compounded receipts stay in the HSA receipt file as documented qualified expenses from the period when they were legal and prescribed.
How do I verify my pharmacy is a 503A facility?▼
Ask the telehealth service which compounding pharmacy fills your prescription, then cross-reference that pharmacy with your state board of pharmacy license records. 503A pharmacies are traditional compounding pharmacies licensed at the state level and operating under section 503A of the FDC Act, which limits them to patient-specific compounding from valid prescriptions. 503B outsourcing facilities are federally registered with the FDA and operate under section 503B for mass production. Compounded semaglutide post-February 2025 must come from a 503A facility under your individual prescription to remain legal.
Compounded vs brand-name - which is better?▼
Different products for different situations. Brand-name Wegovy or Ozempic from Novo Nordisk is FDA-approved, fully studied in registration trials, manufactured to FDA-approved quality standards, and the default clinical choice when insurance covers it. Compounded semaglutide from a 503A pharmacy is a legitimate clinical alternative when (a) your provider determines it is appropriate, (b) the pharmacy is 503A operating under a patient-specific prescription, and (c) the formulation contains active semaglutide base (not salt-form). The right choice depends on your clinical situation, insurance status, and provider recommendation. Talk to your provider before assuming one is automatically better than the other.
Is Gala oral semaglutide different from injectable compounded semaglutide?▼
Yes. Gala prescribes oral semaglutide capsules compounded by a 503A pharmacy. Most other compounded GLP-1 programs (Hims, Strut, MEDVi, LifeMD, Remedy Meds, Shed) prescribe injectable compounded semaglutide. Oral compounded semaglutide is a lower-dose, easier-compliance option but has different bioavailability than injectable - more of the active ingredient is lost during gastrointestinal absorption. Both are HSA-eligible when the prescription, diagnosis, and 503A pharmacy conditions are met. Talk to your provider about which route fits your goals.
What about compounded tirzepatide - same HSA story?▼
No, different regulatory standing. Tirzepatide (Eli Lilly's drug, sold as Mounjaro and Zepbound) is NOT on the FDA shortage list. It was removed earlier than semaglutide. Without a shortage declaration, 503A pharmacies have a thinner legal basis to compound tirzepatide than semaglutide. The HSA eligibility math is the same (prescription-medicines rule plus diagnosis), but the regulatory risk of disruption is higher and compounded tirzepatide programs face active FDA challenge. Treat compounded tirzepatide as a higher-risk path than compounded semaglutide and discuss the regulatory situation with your provider before committing to a long course.
Can I use HSA for the telehealth visit fee too?▼
Yes. The telehealth visit fee, the prescription, and the compounded medication all qualify as HSA-eligible medical expenses under IRC 213(d) when the visit is for diagnosis or treatment of a qualifying condition. Keep the receipt for the visit fee alongside the pharmacy receipt and chart note. Many telehealth services bundle the visit and the first month of medication into a single charge - the entire bundled charge is HSA-eligible because every component is a qualified medical expense.
What documentation should I keep?▼
Five documents. The prescription from your telehealth provider showing compounded semaglutide and the indication. The chart note documenting the qualifying diagnosis with an ICD-10 code (E66.x for obesity, E11.x for T2D). The pharmacy receipt or invoice from the compounding pharmacy showing the medication, date, and amount paid. The compounding pharmacy's name and license information so you can verify 503A status. A Letter of Medical Necessity from the prescribing provider if your HSA administrator requests one for audit defense. Save digital scans in your HSA receipt file. Seven years is the conservative retention standard.
